30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

CartiHeal announced successful enrollment of the first Belgian patient in the Agili-C™ Investigational Device Exemption pivotal study. The study received FDA approval at the end of 2016. To date, in the U.S., Europe and Israel, >80 patients have been enrolled and treated. The trial's objective is to demonstrate superiority of the Agili-C implant vs. microfracture and debridement for the treatment of cartilage or osteochondral defects, in both arthritic knees and knees without degenerative changes (CartiHeal, 8/29/18)